TTNPB 是一种RAR激动剂。在使用人RARs进行竞争性结合实验中，作用于RARα，RARβ和RARγ，IC50分别为 5.1 nM，4.5 nM 和? 9.3 nM。

TTNPB, a potent RAR agonist, inhibits binding of [3H]tRA of human RARα (IC50: 5.1 nM), β (IC50: 4.5 nM), and γ (IC50: 9.3 nM), respectively.

通过诱导细胞凋亡,TTNPB（0.25 mg/kg）可抑制MXT-HI和MXT-HS模型的生长.

在条件培养基培养72 h,TTNPB可使JEG-3细胞中小鼠mRARα（EC50：2.0 nM）、β（EC50：1.1 nM）以及γ（EC50：0.8 nM）转录活性增加。TTNPB与核视黄酸受体的结合亲和力较高,从而抑制[3H]tRA与mRARα（IC50：3.8 nM）、 β（IC50：4.0 nM）以及γ（IC50：4.5 nM）的结合。通过诱导G1细胞周期阻滞,TTNPB对雌激素受体-阳性乳腺癌细胞和正常人体乳腺上皮细胞的生长具有抑制作用。TTNPB浓度依赖性地减少ES-D3细胞分化。

Binding assays: Binding assays are performed as previously described (Allenby et al., 1993, 1994). Briefly, labeled and unlabeled retinoids are added to nucleosol or cytosolic fractions in ethanol so that the total amount of ethanol added is constant in all tubes and did not exceed 2% of the incubation volume. The receptor preparations are incubated with retinoids at 4°C for 4–6 hr. Sephadex PD-10 desalting columns are used to separate bound radioligand from free radioligand after equilib- rium is achieved. For competitive binding assays, varying concentrations of unlabeled competing ligand are incubated with the appropriate nucleosol or cytosol in the presence of a fixed concentration of [3H]tRA (sp. act. 49.3 Ci/mmol) or [3H]9-cis RA (sp. act. 24.0 Ci/mmol). Final concentrations of [3H] tRA and [3H]9-cis RA for nuclear receptor binding assays are 5 nM. Final concentrations of [3H] tRA for CRABP binding assays is 30 nM. The IC50s are calculated as described above (DeLean et al., 1978). For saturation kinetics, increasing concentrations of radiolabeled ligand ([3H]tRA sp. act. 49.3 Ci/mmol, [3H]TTNPB sp. act. 5.5 Ci/ mmol) are added to the nucleosol of the appropriate receptor subtype in the presence (nonspecific binding) or absence (total binding) of a 100-fold molar excess of the corresponding unlabeled retinoid. Specific binding is defined as the total binding minus nonspecific binding. Saturation kinetics are calculated as previously described (Scatchard, 1949; Grippo and Gudas, 1987; Levin et al., 1992).

Human mammary epithelial cells are maintained in Mammary Epithelial Basal Medium (MEBM) supplemented with the Mammary Epithelial Growth Media (MEGM) bullet kit. 184 and 184B5 cells are maintained in MEBM sodium-bicarbonate free (MEBM-SBF) supplemented with the MEGM bullet kit, isoproterenol (10 μM), and transferrin (5 μg/ml). MCF10A cell lines are maintained in DME/F12 containing 5% heat inactivated horse serum, penicillin/streptomycin (100 μg/ml and 100 μg/ml), hydrocortisone (1.4 μM), insulin (10 μg/ml), choleratoxin (100 ng/ml), and EGF (20 ng/ml). Breast cancer cell lines are maintained in Improved MEM Zinc Option containing 10% fetal bovine serum, 1% glutamine, and 1% penicillin/streptomycin. For growth assays, cells are treated with the different retinoids for the specified number of days with media and treatment changes every other day in T47D cells and every 2 days in 184 cells. Cell proliferation is measured according to the protocol for the CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay. This colorimetric assay determines the number of viable cells in a sample. Each point represents samples done in quadruplicate.(Only for Reference)

71441-28-6

C24H28O2

348.486

Ro 13-7410,AGN-191183;AGN191183;Ro 13-7410;Arotinoid acid

DMSO:3.5 mg/mL (10 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years